论文部分内容阅读
４５例经临床和脑ＣＴ扫描／ＭＲＩ确诊的急性期脑梗塞（ＣＩ）患者被随机分成东菱精纯克栓酶（巴曲酶，ＤＦ－５２１）治疗组（３０例）和血液稀释对照组（１５例）。二组患者均于治疗前和治疗后１周作神经功能缺损评分，结合治疗后患者的病残程度，评定临床疗效；同时作凝血功能、血粘度和血小板聚集率等实验室观测。结果表明，早期静脉滴注ＤＦ－５２１治疗ＣＩ安全、有效，总有效率为９３．３％，明显高于对照组（４６．７％，Ｐ＜０．０１）。ＤＦ－５２１能明显降低ＣＩ患者血粘度和血浆纤维蛋白原浓度，对ＡＤＰ诱导的血小板聚集反应有显著抑制作用，可作为ＣＩ早期抗栓溶栓疗法的一种新选择。
Forty-five patients with acute cerebral infarction (CI) diagnosed by clinical and CT scan / MRI were randomly divided into two groups: the DF-521 treatment group (Batroxobin, DF-521) and the Hemodilution control group (15 cases). Two groups of patients before treatment and 1 week after treatment for neurological deficit score, combined with the patient’s degree of sick after treatment to assess clinical efficacy; at the same time for coagulation, blood viscosity and platelet aggregation rate and other laboratory observations. The results showed that early intravenous infusion of DF-521 in the treatment of CI was safe and effective, with a total effective rate of 93.3%, significantly higher than that of the control group (46.7%, P <0.01). DF-521 can significantly reduce the blood viscosity of CI patients and plasma fibrinogen concentration, ADP-induced platelet aggregation response was significantly inhibited, as an early CI anti-thrombolytic therapy a new choice.